→ Paolo Paoletti, the former president of GSK’s oncology R&D group, has taken the helm at Abingworth-backed GammaDelta Therapeutics. “I’m extremely excited to take on this role to further advance the pioneering research on gamma delta (γδ) T cells of the company’s founders, Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute,” Paoletti said in a statement. “The unique properties of γδ T cells, coupled with the proprietary knowledge of the company offer great prospects for the development of innovative immunotherapies for many forms of cancers, including solid tumours, and potentially auto-inflammatory diseases.” Pfizer vet Natalie Mount joined the biotech as CSO.
→ Blueprint CEO Jeff Albers has inked a new lease for 100,000 square feet in Cambridge, MA, according to the Boston Business Journal.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription